Business Context and Reporting Period
This Form 8-K was filed by Pro-Pharmaceuticals, Inc. on April 22, 2011. The report discloses the entry into a Material Definitive Agreement with Sigma-Aldrich, Inc. The registrant is incorporated in Nevada and maintains its principal executive offices in Newton, Massachusetts.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the execution of a contractual agreement rather than financial performance results.
Material Changes and Agreements
On April 22, 2011, the Company entered into a Master Services Agreement with Sigma-Aldrich, Inc. Key terms include:
- Scope of Services: Sigma-Aldrich will provide clinical trial services, statistical programming, data management, regulatory support, project management, central laboratory services, and pre-clinical services based on work orders.
- Term: The agreement has a three-year term unless terminated earlier.
- Payment Structure: The Company is required to pay fees, expenses, and pass-through costs according to budgets and schedules defined in individual work orders.
- Intellectual Property: The Company retains exclusive property rights to all data, inventions, and improvements resulting from the services. Sigma-Aldrich has agreed to assign all related patent rights to the Company.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard contractual obligations. The agreement is contingent upon the issuance of work orders, meaning future costs and service volumes are not fixed at the time of this filing.
Investor Verification Checklist
- Review the full text of the Master Services Agreement (Exhibit 10.1) for specific fee structures and termination clauses.
- Monitor future filings for the issuance of specific work orders under this agreement to assess actual financial impact.
- Verify the Company's cash position to ensure it can fund the variable costs associated with the upcoming clinical and pre-clinical services.